Ya-Yi Chen1,2, Tzu-Ting Chen3, Ya-Hsuan Chao4, Wen-Ho Chuo5, Chieh-Shan Wu6,7, Ruo-Han Tseng8,*, Chieh-Chen Huang9,*
BIOCELL, Vol.49, No.9, pp. 1733-1748, 2025, DOI:10.32604/biocell.2025.067011
- 25 September 2025
Abstract Objectives: Professional antigen-presenting cells known as dendritic cells (DCs) assist as a connection between the innate and adaptive components of the immune response. DCs are attractive targets for immunomodulatory drugs because of their crucial function in triggering immunity. This study set out to examine, for the first time, how hibifolin affected mouse bone-marrow derived (BMDCs) dendritic cells, triggered by lipopolysaccharide (LPS) in vitro. Additionally, a mouse model of contact hypersensitivity (CHS) was used to assess its possible therapeutic effects in vivo. Methods: LPS was administered to BMDCs with or without hibifolin. Major Histocompatibility Complex (MHC) class II,… More >